Oncoceutics: Real-Time Solutions for Cancer Treatment

Joshua Allen, Senior Vice President of Research and Development at Oncoceutics joins us to explain a novel group of compounds called imipridones that he helped to create which target specific mutations in an wide array of cancer types. ONC201, the first that he personally discovered, is now being used in…

Continue reading

Trailblazing to a Cure: DIPG-Treatment Advisory Council (G-TAC)

G-TAC founder and Executive Director of MaxCure Foundation Jonathan Agin, and G-TAC Medical Advisory Board Member Dr. Sabine Mueller, top neuro-oncology researcher and clinical expert at UCSF, discuss a new concierge-type service for families of the newly-diagnosed with DIPG (diffuse intrinsic pontine glioma) to more expediently direct them to more…

Continue reading